Efficacy and tolerability of D-β-hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (KETO-ALS)-a randomised, placebo-controlled, double-blind study.

Herrmann C, Jagodzinski L, Elmas Z, Herschmann T, Fröhlich E, Bachhuber F, Ruschitzka T, Willkomm F, Parlak Ö, Weiland U, Becker F, Richter L, Wiesenfarth M, Uzelac Z, Michels S, Witzel S, Tumani H, Weishaupt JH, Maier L, Mayer B, Dreyhaupt J, Schuster J, Dorst J

Open source

DOI: 10.1016/j.eclinm.2026.104272
Published: 2026 Nov
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2026.104272,
  title = {Efficacy and tolerability of D-β-hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (KETO-ALS)-a randomised, placebo-controlled, double-blind study.},
  author = {Herrmann C and Jagodzinski L and Elmas Z and Herschmann T and Fröhlich E and Bachhuber F and Ruschitzka T and Willkomm F and Parlak Ö and Weiland U and Becker F and Richter L and Wiesenfarth M and Uzelac Z and Michels S and Witzel S and Tumani H and Weishaupt JH and Maier L and Mayer B and Dreyhaupt J and Schuster J and Dorst J},
  year = {2026},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2026.104272},
  url = {https://doi.org/10.1016/j.eclinm.2026.104272}
}

RIS

TY  - JOUR
TI  - Efficacy and tolerability of D-β-hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (KETO-ALS)-a randomised, placebo-controlled, double-blind study.
AU  - Herrmann C
AU  - Jagodzinski L
AU  - Elmas Z
AU  - Herschmann T
AU  - Fröhlich E
AU  - Bachhuber F
AU  - Ruschitzka T
AU  - Willkomm F
AU  - Parlak Ö
AU  - Weiland U
AU  - Becker F
AU  - Richter L
AU  - Wiesenfarth M
AU  - Uzelac Z
AU  - Michels S
AU  - Witzel S
AU  - Tumani H
AU  - Weishaupt JH
AU  - Maier L
AU  - Mayer B
AU  - Dreyhaupt J
AU  - Schuster J
AU  - Dorst J
PY  - 2026
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2026.104272
UR  - https://doi.org/10.1016/j.eclinm.2026.104272
ER  -

APA

C, H., L, J., Z, E., T, H., E, F., F, B., T, R., F, W., Ö, P., U, W., F, B., L, R., M, W., Z, U., S, M., S, W., H, T., JH, W., L, M., B, M., J, D., J, S., & J, D. (2026). Efficacy and tolerability of D-β-hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (KETO-ALS)-a randomised, placebo-controlled, double-blind study.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104272

Source records

pubmed · retrieved 2026-11-10T12:15:41.500Z
europe-pmc · retrieved 2026-11-10T12:15:41.506Z
doaj · retrieved 2026-11-10T12:15:41.504Z